Foghorn Therapeutics Inc. current report, 24 April 2023

Full document

Foghorn Therapeutics Inc. — Form 8-K Summary

Reporting date: April 24, 2023. The filing reports an update to the company’s FHD-609 clinical program in synovial sarcoma and SMARCB1-deleted tumors.

Business Context and Program Update

  • Foghorn completed enrollment in the dose-escalation portion of the FHD-609 study and identified a maximum tolerated dose.
  • The study involves patients with synovial sarcoma and SMARCB1-deleted tumors.

Material Changes and Clinical Safety Event

  • Enrollment was paused after a patient with synovial sarcoma experienced a Grade 4 QTc prolongation event at the second-highest dose.
  • Following communications with U.S. and European regulators, the FDA placed the U.S. study on partial clinical hold.
  • Patients already enrolled and benefiting from treatment may continue dosing.
  • The company stated that it is not currently planning to pursue a dose-expansion study independently.

Financial Metrics, Liquidity, and Debt

This Form 8-K does not provide revenue, profit or loss, cash flow, operating margin, debt, liquidity, cash balance, or other financial metrics.

Outlook, Risks, and Unusual Items

  • The partial clinical hold and enrollment pause may delay or limit further development of FHD-609.
  • The Grade 4 QTc prolongation event represents a material clinical safety risk and may affect the program’s benefit-risk assessment.
  • Future development plans are uncertain because the company is not currently planning an independent dose-expansion study.
  • The filing does not provide revised financial guidance or a quantified estimate of the potential financial impact.

Key Facts for Investors to Verify

  • Status and scope of the FDA partial clinical hold.
  • Whether and when enrollment may resume.
  • Additional safety findings, including the investigation and recurrence risk of QTc prolongation.
  • Whether a partner or other sponsor may pursue dose expansion or further development.
  • Foghorn’s current cash runway and the potential effect of the program update on capital requirements, as these figures are not included in this filing.